| Christopher Vera, DO | |
|
1600 Providence Dr, Attn: Traci Mitchell - Admn, Waco, TX 76707-2261 | |
| (254) 313-4200 | |
| (254) 313-4326 |
| Full Name | Christopher Vera |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 10 Years |
| Location | 1600 Providence Dr, Waco, Texas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1760863153 | NPI | - | NPPES |
| 362939601 | Other | TX | MEDICAID |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | BP10054661 (Texas) | Secondary |
| 207Q00000X | Family Medicine | Q9539 (Texas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Providence Hospice | Waco, TX | Hospice |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Heart Of Texas Community Health Center, Inc. | 1153370242 | 95 |
News Archive
Arizona State University researchers to date have received more than $32 million in stimulus package research grants. For ASU, which has played a very active role in attracting this additional funding, much of these research funds have gone for projects that meet challenges currently confronting society.
Vivakor™, Inc. (OTCBB: VIVK) today announced the results of independent, third-party validation testing of its VivaBlend™ nutraceutical product. VivaBlend is a powerful extract developed by the scientists at Vivakor and is derived from over 18 highly bioactive fruits, vegetables and legumes. Through a proprietary formulation and extraction process, Vivakor scientists have maximized the health benefits of VivaBlend by creating an optimum blend of super-antioxidants and powerful plant phenolics and flavonoids.
ProUroCare Medical, Inc. today announced the completion of a National Institute of Health and National Cancer Institute-supported clinical study. The study's purpose was to evaluate the ability of the company's ProUroScan imaging system to visualize and document abnormalities in the prostate detected or monitored by the digital rectal exam (DRE).
The Cell Therapy Catapult has published its annual analysis of the UK preclinical and clinical research landscapes with the release of its UK Clinical and Pre-Clinical Trials Databases. These show a 24% rise in the number of clinical trials and an increase of 22% in the number of pre-clinical projects. Sector growth came in the key areas of oncology, neurology, ophthalmology and cardiovascular.
Specifically for oncology drug development applications, the YSI 2950 biochemistry analyzer is used to measure analytes such as glucose, glutamine, glutamate, lactate, providing a simple, automated analysis of bioprocess cell culture samples, with accurate results in less than a minute.
› Verified 8 days ago
| Entity Name | Mclennan County Medical Education And Research Foundation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1689651440 PECOS PAC ID: 0042205155 Enrollment ID: O20040419000208 |
News Archive
Arizona State University researchers to date have received more than $32 million in stimulus package research grants. For ASU, which has played a very active role in attracting this additional funding, much of these research funds have gone for projects that meet challenges currently confronting society.
Vivakor™, Inc. (OTCBB: VIVK) today announced the results of independent, third-party validation testing of its VivaBlend™ nutraceutical product. VivaBlend is a powerful extract developed by the scientists at Vivakor and is derived from over 18 highly bioactive fruits, vegetables and legumes. Through a proprietary formulation and extraction process, Vivakor scientists have maximized the health benefits of VivaBlend by creating an optimum blend of super-antioxidants and powerful plant phenolics and flavonoids.
ProUroCare Medical, Inc. today announced the completion of a National Institute of Health and National Cancer Institute-supported clinical study. The study's purpose was to evaluate the ability of the company's ProUroScan imaging system to visualize and document abnormalities in the prostate detected or monitored by the digital rectal exam (DRE).
The Cell Therapy Catapult has published its annual analysis of the UK preclinical and clinical research landscapes with the release of its UK Clinical and Pre-Clinical Trials Databases. These show a 24% rise in the number of clinical trials and an increase of 22% in the number of pre-clinical projects. Sector growth came in the key areas of oncology, neurology, ophthalmology and cardiovascular.
Specifically for oncology drug development applications, the YSI 2950 biochemistry analyzer is used to measure analytes such as glucose, glutamine, glutamate, lactate, providing a simple, automated analysis of bioprocess cell culture samples, with accurate results in less than a minute.
› Verified 8 days ago
| Entity Name | Heart Of Texas Community Health Center, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1568191492 PECOS PAC ID: 1153370242 Enrollment ID: O20050114000813 |
News Archive
Arizona State University researchers to date have received more than $32 million in stimulus package research grants. For ASU, which has played a very active role in attracting this additional funding, much of these research funds have gone for projects that meet challenges currently confronting society.
Vivakor™, Inc. (OTCBB: VIVK) today announced the results of independent, third-party validation testing of its VivaBlend™ nutraceutical product. VivaBlend is a powerful extract developed by the scientists at Vivakor and is derived from over 18 highly bioactive fruits, vegetables and legumes. Through a proprietary formulation and extraction process, Vivakor scientists have maximized the health benefits of VivaBlend by creating an optimum blend of super-antioxidants and powerful plant phenolics and flavonoids.
ProUroCare Medical, Inc. today announced the completion of a National Institute of Health and National Cancer Institute-supported clinical study. The study's purpose was to evaluate the ability of the company's ProUroScan imaging system to visualize and document abnormalities in the prostate detected or monitored by the digital rectal exam (DRE).
The Cell Therapy Catapult has published its annual analysis of the UK preclinical and clinical research landscapes with the release of its UK Clinical and Pre-Clinical Trials Databases. These show a 24% rise in the number of clinical trials and an increase of 22% in the number of pre-clinical projects. Sector growth came in the key areas of oncology, neurology, ophthalmology and cardiovascular.
Specifically for oncology drug development applications, the YSI 2950 biochemistry analyzer is used to measure analytes such as glucose, glutamine, glutamate, lactate, providing a simple, automated analysis of bioprocess cell culture samples, with accurate results in less than a minute.
› Verified 8 days ago
| Entity Name | Concord Medical Group Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1083630610 PECOS PAC ID: 0446296818 Enrollment ID: O20050707000531 |
News Archive
Arizona State University researchers to date have received more than $32 million in stimulus package research grants. For ASU, which has played a very active role in attracting this additional funding, much of these research funds have gone for projects that meet challenges currently confronting society.
Vivakor™, Inc. (OTCBB: VIVK) today announced the results of independent, third-party validation testing of its VivaBlend™ nutraceutical product. VivaBlend is a powerful extract developed by the scientists at Vivakor and is derived from over 18 highly bioactive fruits, vegetables and legumes. Through a proprietary formulation and extraction process, Vivakor scientists have maximized the health benefits of VivaBlend by creating an optimum blend of super-antioxidants and powerful plant phenolics and flavonoids.
ProUroCare Medical, Inc. today announced the completion of a National Institute of Health and National Cancer Institute-supported clinical study. The study's purpose was to evaluate the ability of the company's ProUroScan imaging system to visualize and document abnormalities in the prostate detected or monitored by the digital rectal exam (DRE).
The Cell Therapy Catapult has published its annual analysis of the UK preclinical and clinical research landscapes with the release of its UK Clinical and Pre-Clinical Trials Databases. These show a 24% rise in the number of clinical trials and an increase of 22% in the number of pre-clinical projects. Sector growth came in the key areas of oncology, neurology, ophthalmology and cardiovascular.
Specifically for oncology drug development applications, the YSI 2950 biochemistry analyzer is used to measure analytes such as glucose, glutamine, glutamate, lactate, providing a simple, automated analysis of bioprocess cell culture samples, with accurate results in less than a minute.
› Verified 8 days ago
| Entity Name | Concord Medical Group Of Texas Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1750790762 PECOS PAC ID: 7810117223 Enrollment ID: O20141007002567 |
News Archive
Arizona State University researchers to date have received more than $32 million in stimulus package research grants. For ASU, which has played a very active role in attracting this additional funding, much of these research funds have gone for projects that meet challenges currently confronting society.
Vivakor™, Inc. (OTCBB: VIVK) today announced the results of independent, third-party validation testing of its VivaBlend™ nutraceutical product. VivaBlend is a powerful extract developed by the scientists at Vivakor and is derived from over 18 highly bioactive fruits, vegetables and legumes. Through a proprietary formulation and extraction process, Vivakor scientists have maximized the health benefits of VivaBlend by creating an optimum blend of super-antioxidants and powerful plant phenolics and flavonoids.
ProUroCare Medical, Inc. today announced the completion of a National Institute of Health and National Cancer Institute-supported clinical study. The study's purpose was to evaluate the ability of the company's ProUroScan imaging system to visualize and document abnormalities in the prostate detected or monitored by the digital rectal exam (DRE).
The Cell Therapy Catapult has published its annual analysis of the UK preclinical and clinical research landscapes with the release of its UK Clinical and Pre-Clinical Trials Databases. These show a 24% rise in the number of clinical trials and an increase of 22% in the number of pre-clinical projects. Sector growth came in the key areas of oncology, neurology, ophthalmology and cardiovascular.
Specifically for oncology drug development applications, the YSI 2950 biochemistry analyzer is used to measure analytes such as glucose, glutamine, glutamate, lactate, providing a simple, automated analysis of bioprocess cell culture samples, with accurate results in less than a minute.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Christopher Vera, DO 1600 Providence Dr, Attn: Traci Mitchell - Admn, Waco, TX 76707-2261 Ph: (254) 313-4200 | Christopher Vera, DO 1600 Providence Dr, Attn: Traci Mitchell - Admn, Waco, TX 76707-2261 Ph: (254) 313-4200 |
News Archive
Arizona State University researchers to date have received more than $32 million in stimulus package research grants. For ASU, which has played a very active role in attracting this additional funding, much of these research funds have gone for projects that meet challenges currently confronting society.
Vivakor™, Inc. (OTCBB: VIVK) today announced the results of independent, third-party validation testing of its VivaBlend™ nutraceutical product. VivaBlend is a powerful extract developed by the scientists at Vivakor and is derived from over 18 highly bioactive fruits, vegetables and legumes. Through a proprietary formulation and extraction process, Vivakor scientists have maximized the health benefits of VivaBlend by creating an optimum blend of super-antioxidants and powerful plant phenolics and flavonoids.
ProUroCare Medical, Inc. today announced the completion of a National Institute of Health and National Cancer Institute-supported clinical study. The study's purpose was to evaluate the ability of the company's ProUroScan imaging system to visualize and document abnormalities in the prostate detected or monitored by the digital rectal exam (DRE).
The Cell Therapy Catapult has published its annual analysis of the UK preclinical and clinical research landscapes with the release of its UK Clinical and Pre-Clinical Trials Databases. These show a 24% rise in the number of clinical trials and an increase of 22% in the number of pre-clinical projects. Sector growth came in the key areas of oncology, neurology, ophthalmology and cardiovascular.
Specifically for oncology drug development applications, the YSI 2950 biochemistry analyzer is used to measure analytes such as glucose, glutamine, glutamate, lactate, providing a simple, automated analysis of bioprocess cell culture samples, with accurate results in less than a minute.
› Verified 8 days ago
Allison L Hulme, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 1600 Providence Dr, Waco, TX 76707 Phone: 254-750-8200 Fax: 254-750-8326 | |
Timothy Martindale, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 7104 New Sanger Rd, Waco, TX 76712 Phone: 254-741-1113 Fax: 254-741-1342 | |
Dr. Brian Douglas Bull, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 851 North Loop 340, Waco, TX 76705 Phone: 254-202-7500 Fax: 254-202-7599 | |
Dr. Matthew R Porter, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 600 W. State Hwy 6, Waco, TX 76712 Phone: 254-313-6700 Fax: 254-313-4531 | |
Lianda Mirella Martinez, Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 600 Franklin Ave, Suite B-c, Waco, TX 76701 Phone: 254-537-6590 Fax: 254-537-6599 | |
Jacob Lutgen, Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 1600 Providence Dr, Waco, TX 76707 Phone: 254-313-4200 | |
Dr. Aman A Shah, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 100 Hillcrest Medical Blvd, Waco, TX 76712 Phone: 254-202-2000 |